Page 52 - Genentech News Today

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective...

Treatment with both PD-1 and TIGIT immunotherapy alongside chemotherapy demonstrated improved progression-free (PFS) and overall survival (OS) compared with chemotherapy alone in patients with esophageal squamous cell carcinoma (ESCC).

The co-founders of PPA discuss the importance of advocacy work at this point in the development of the psychedelic medicine industry to help cement pharmacist’s role in the continuum of care.

This cyclical sector has suffered, post-pandemic, but signs of a recovery are appearing.

Baxalta Inc. and Baxalta GmbH (Baxalta) appealed a district court decision that the claims of U.S. Patent No. 7,033,590 were invalid for lack of enablement.

The U.S. National Security Commission on Emerging Biotechnology issued its first report since its creation through the National Defense Authorization Act of FY2022.

/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche received European Commission (EC) marketing authorization of...

Subcutaneous injection offers the potential for a faster, more convenient alternative to intravenous infusion and is preferred by cancer patients, nurses and physicians1-5Tecentriq SC reduces...

Last year saw the highest number of life science layoffs in San Mateo County in roughly a decade, and more than triple the amount from the previous year, indicating the

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has granted marketing authorisation for Tecentriq® SC (atezolizumab), the European Union (EU)’s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) injection. Last year, more than 38,000 people in the EU received ...